345 related articles for article (PubMed ID: 24657302)
21. [Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China].
Xia W; Wang SS; Hu H; Zhao FL; Xu F; Hong RX; Jiang KK; Yuan ZY; Shi YX; Zhao K; Huang JJ; Xue C; Bi XW; Lu QY; An X; Zhang JM
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):861-867. PubMed ID: 33113628
[No Abstract] [Full Text] [Related]
22. Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis.
Li E; Mezzio DJ; Campbell D; Campbell K; Lyman GH
JCO Oncol Pract; 2021 Aug; 17(8):e1235-e1245. PubMed ID: 33793342
[TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.
Chan KK; Siu E; Krahn MD; Imrie K; Alibhai SM
J Clin Oncol; 2012 Apr; 30(10):1064-71. PubMed ID: 22393098
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R
Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of primary prophylaxis of febrile neutropenia with pegfilgrastim in docetaxel, cisplatin and 5-fluorouracil therapy for esophageal cancer.
Ichimura T; Nomura H; Shimizu H; Machida Y; Suzuki K
Pharmazie; 2021 Sep; 76(9):450-454. PubMed ID: 34481537
[No Abstract] [Full Text] [Related]
26. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
Naeim A; Henk HJ; Becker L; Chia V; Badre S; Li X; Deeter R
BMC Cancer; 2013 Jan; 13():11. PubMed ID: 23298389
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
Younis T; Rayson D; Jovanovic S; Skedgel C
Breast Cancer Res Treat; 2016 Oct; 159(3):425-32. PubMed ID: 27572552
[TBL] [Abstract][Full Text] [Related]
31. Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis.
Billingsley CC; Cohn DE; Crim AK; Li Q; O'Malley DM; Havrilesky LJ
Cancer Treat Res Commun; 2018; 14():21-25. PubMed ID: 30104004
[TBL] [Abstract][Full Text] [Related]
32. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Wang L; Baser O; Kutikova L; Page JH; Barron R
Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
34. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
[TBL] [Abstract][Full Text] [Related]
35. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
36. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.
Weycker D; Li X; Barron R; Li Y; Reiner M; Kartashov A; Figueredo J; Tzivelekis S; Garcia J
Support Care Cancer; 2016 Jun; 24(6):2481-90. PubMed ID: 26670915
[TBL] [Abstract][Full Text] [Related]
37. Evaluating the safety and effectiveness of PegaGen
Jenabian A; Ehsanpour A; Mortazavizadeh SMR; Raafat J; Razavi M; Khosravi A; Seifi S; Salimi B; Anjidani N; Kafi H
Support Care Cancer; 2022 Oct; 30(10):8151-8158. PubMed ID: 35792924
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
[TBL] [Abstract][Full Text] [Related]
39. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.
Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
Curr Med Res Opin; 2017 Dec; 33(12):2107-2113. PubMed ID: 28958157
[TBL] [Abstract][Full Text] [Related]
40. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
